National Heart, Lung, and Blood Institute (NHLBI): Thrombocytopenia trials

The registry lists 10 Thrombocytopenia studies with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor. 2 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 7No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)RecruitingNCT04304820Phase 2Results posted
• Screening for Hematology Branch ProtocolsEnrolling by invitationNCT00001620
• Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe ThrombocytopeniaCompletedNCT02298933Phase 2Results posted
• Eltrombopag With Standard Immunosuppression for Severe Aplastic AnemiaActive, not recruitingNCT01623167Phase 1/2Results posted
• Eltrombopag for Moderate Aplastic AnemiaCompletedNCT01328587Phase 2Results posted
• A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)CompletedNCT00961064Phase 2Results posted
• A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia PatientsCompletedNCT00922883Phase 2Results posted
• Three Immunosuppressive Treatment Regimens for Severe Aplastic AnemiaCompletedNCT00260689Phase 2Results posted
• Treatment of Autoimmune Thrombocytopenia (AITP)CompletedNCT00001630Phase 1
• Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With CyclosporineCompletedNCT00001533Phase 1